Stockman Wealth Management Inc. Purchases 6,375 Shares of Merck & Co., Inc. (NYSE:MRK)

by · The Cerbat Gem

Stockman Wealth Management Inc. increased its position in Merck & Co., Inc. (NYSE:MRK – Free Report) by 5.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 115,921 shares of the company’s stock after purchasing an additional 6,375 shares during the quarter. Merck & Co., Inc. makes up 2.0% of Stockman Wealth Management Inc.’s portfolio, making the stock its 14th largest holding. Stockman Wealth Management Inc.’s holdings in Merck & Co., Inc. were worth $13,164,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of MRK. Itau Unibanco Holding S.A. acquired a new position in Merck & Co., Inc. during the second quarter worth $39,000. Abich Financial Wealth Management LLC raised its stake in Merck & Co., Inc. by 121.8% during the second quarter. Abich Financial Wealth Management LLC now owns 326 shares of the company’s stock worth $40,000 after acquiring an additional 179 shares in the last quarter. Quarry LP acquired a new position in Merck & Co., Inc. during the second quarter worth $42,000. Strategic Financial Concepts LLC raised its stake in Merck & Co., Inc. by 1,475.6% during the second quarter. Strategic Financial Concepts LLC now owns 35,057 shares of the company’s stock worth $43,000 after acquiring an additional 32,832 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC raised its stake in Merck & Co., Inc. by 47.5% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 379 shares of the company’s stock worth $43,000 after acquiring an additional 122 shares in the last quarter. 76.07% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the company. Evercore ISI upgraded Merck & Co., Inc. to a “strong-buy” rating in a research note on Tuesday, July 30th. Morgan Stanley lowered their target price on Merck & Co., Inc. from $130.00 to $123.00 and set an “equal weight” rating for the company in a research note on Friday, November 1st. Citigroup lowered their target price on Merck & Co., Inc. from $140.00 to $130.00 and set a “buy” rating for the company in a research note on Friday, October 25th. UBS Group decreased their price target on Merck & Co., Inc. from $142.00 to $136.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. Finally, Wells Fargo & Company decreased their price target on Merck & Co., Inc. from $125.00 to $110.00 and set an “equal weight” rating on the stock in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating, ten have assigned a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Merck & Co., Inc. has a consensus rating of “Moderate Buy” and a consensus target price of $130.86.

Get Our Latest Stock Report on MRK

Merck & Co., Inc. Stock Up 1.7 %

Shares of NYSE:MRK traded up $1.75 during trading on Friday, hitting $102.92. 9,208,036 shares of the company were exchanged, compared to its average volume of 9,553,251. The stock has a market cap of $260.35 billion, a price-to-earnings ratio of 21.58, a P/E/G ratio of 1.44 and a beta of 0.40. Merck & Co., Inc. has a fifty-two week low of $98.60 and a fifty-two week high of $134.63. The firm has a fifty day moving average price of $110.74 and a two-hundred day moving average price of $119.99. The company has a current ratio of 1.47, a quick ratio of 1.22 and a debt-to-equity ratio of 0.80.

Merck & Co., Inc. (NYSE:MRK – Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $1.50 by $0.07. The business had revenue of $16.66 billion for the quarter, compared to analyst estimates of $16.47 billion. Merck & Co., Inc. had a return on equity of 37.32% and a net margin of 19.23%. The firm’s revenue was up 4.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.13 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 7.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).